Overview: HLA-B27 Flow Cytometry TestIntroduction: The HLA-B27 Flow Cytometry Test detects HLA-B27 antigen via flow cytometry to diagnose autoimmune diseases like ankylosing spondylitis, causing back pain. Following 2023 ACR guidelines, it uses flow cytometry for high specificity, aiding autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected spondyloarthropathies.
Other Names: HLA-B27 Flow Assay, Ankylosing Spondylitis Flow Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA-B27 testing began in the 1970s with autoimmune disease research. Flow cytometry-based assays improved in the 1990s, enhancing diagnostic precision.
Purpose: Diagnoses autoimmune diseases like ankylosing spondylitis, guides treatment, and detects HLA-B27 in patients with back pain.
Test Parameters: 1. HLA-B27 Antigen
Pretest Condition: No fasting required. Collect whole blood at any time. Report symptoms like back pain, joint stiffness, or uveitis, and list medications.
Specimen: 2-5 mL whole blood (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document back pain, joint stiffness, uveitis, or family history of autoimmune diseases. Include current medications, especially anti-inflammatory drugs, and recent symptoms.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses flow cytometry to detect HLA-B27 antigen on cell surfaces. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for autoimmune diagnosis.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low cell viability may impact detection accuracy.
Clinical Significance: Positive HLA-B27 suggests ankylosing spondylitis or related conditions, guiding anti-inflammatory or immunosuppressive therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult a rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: ESR, CRP, HLA-B27 PCR, or imaging (e.g., MRI of sacroiliac joints) to confirm autoimmune diseases.
Test Limitations: HLA-B27 is not diagnostic alone; clinical correlation is needed. Some HLA-B27-positive individuals may be asymptomatic.
References: ACR Spondyloarthritis Guidelines, 2023; Arthritis & Rheumatology, Ward MM, 2022.
